Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Given this risk, we thought we'd take a look at whether Skye Bioscience (NASDAQ:SKYE) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.

Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...

About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.

Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report)’s stock price rose 24% on Thursday . The company traded as high as $1.81 and last traded at $2.15. Approximately 320,782 shares traded ...

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and ...

On Monday, Oppenheimer maintained an Outperform rating on Skye Bioscience (NASDAQ: SKYE) but reduced the price target from $21.00 to $17.00.

About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.